Review of rabeprazole in the treatment of gastro-oesophageal reflux disease

Bibliography

• FASS R, FENNERTY MB, VAKIL N: Nonerosive reflux disease-current concepts and dilemmas. Am. J. Gastroenterol (2001) 96(2):303–314.
   PubMedGoogle Scholar
• CARLSSON R, DENT J, WATTS R et al.: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur. Gastroenterol Hepatol (1998) 10(2):119–124.
   PubMedGoogle Scholar
• LIND T, HAVELUND T, CARLSSON R et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand. Gastroenterol (1997) 32(10):974–979.
   PubMed Web of Science ®Google Scholar
• HOWARD PJ, MAHER L, PRYDE A, HEADING RC: Symptomatic gastro-oesophageal reflux, abnormal oesophageal acid exposure, and mucosal acid sensitivity are three separate, though related, aspects of gastro-oesophageal reflux disease. Gut (1991) 32(2):128–132.
   PubMedGoogle Scholar
• JOHANSON JF: Epidemiology of esophageal and supraesophageal reflux injuries. Am. Med. (2000) 108(Suppl. 4A):995–1035.
   Google Scholar
• HEADING RC: Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand. Gastroenterol Sapp]. (1999) 231:3–8.
   Google Scholar
• MAHMOOD Z, MCNAMARA D: Gastro-oesophageal reflux disease and ulcer disease. Aliment. Pharmacol Ther. (2003) 18\(Suppl. 3):31–37.
   Google Scholar
• HAYCOX A, EINARSON T, EGGLESTON A: The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand. Gastroenterol Sapp]. (1999) 231:38–47.
   Google Scholar
• SANDLER RS, EVERHART JE, DONOWITZ M et al: The burden of selected digestive diseases in the United States. Gastroenterology (2002) 122(5):1500–1511.
   PubMed Web of Science ®Google Scholar
• NANDURKAR S TN: Epidemiology and natural history of reflux disease. Baillieres Best Pract. Res. Clin. Gastroenterol (2000) 14:743–757.
   PubMedGoogle Scholar
• AGREUS L, TALLEY NJ, NYREN O et al.: Natural history of reflux, dyspepsia and irritable bowel over 7 years in the general population. Gastroenterology (1998) 114(Suppl.):A–917.
   Google Scholar
• DENT J, BRUN J, FENDRICK AM et al: An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut (1999) 44\(Suppl. 2):S1–516.
   Google Scholar
• FASS R, OFMAN JJ, SAMPLINER RE, CAMARGO L, VVENDEL C, FENNERTY MB: The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment. Pharmacol Ther. (2000) 14(4):389–396.
   PubMedGoogle Scholar
• JUUL-HANSEN P, RYDNING A, JACOBSEN CD, HANSEN T: High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand. Gastroenterol (2001) 36(8):806–810.
   PubMedGoogle Scholar
• LOCKE GR 3RD, TALLEY NJ, FETT SL, ZINSMEISTER AR, MELTON LJ 3rd: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 112(5):1448–1456.
   PubMed Web of Science ®Google Scholar
• GALMICHE JP, BARTHELEMY P, HAMELIN B: Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment. Pharmacol The]: (1997) 11(4):765–773.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG D, PARE P, PERICAK D, PYZYK M: Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am. Gastroenterol (2001) 96(10):2849–2857.
   PubMed Web of Science ®Google Scholar
• VENABLES TL, NEWLAND RD, PATEL AC, HOLE J, WILCOCK C, TURBITT ML: Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand. Gastroenterol (1997) 32(10):965–973.
   PubMed Web of Science ®Google Scholar
• HAVELUND T, LIND T, WIKLUND I et al.: Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am. Gastroenterol (1999) 94(7):1782–179.
   PubMedGoogle Scholar
• JOHNSTON BT, MCFARLAND RJ, COLLINS JS, LOVE AH: Symptom index as a marker of gastro-oesophageal reflux disease. Br: J. Surg. (1992) 79(10):1054–105.
   PubMedGoogle Scholar
• HUNT RH: Importance of pH control in the management of GERD. Arch. Intern. Med. (1999) 159(7):649–657.
   PubMed Web of Science ®Google Scholar
• THOMSON AB, CHIBA N, ARMSTRONG D, TOUGAS G, HUNT RH: The second canadian gastroesophageal reflux disease consensus: moving forward to new concepts. Can. Gastroenterol (1998) 12(8):551–556.
   PubMedGoogle Scholar
• KROMER W, KRUGER U, HUBER R, HARTMANN M, STEINIJANS VW: Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology (1998) 56(2):57–70.
   PubMed Web of Science ®Google Scholar
• SACHS G, SHIN JM, MUNSON K et al: Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment. Pharmacol Ther. (2000) 14(11):1383–1401.
   PubMedGoogle Scholar
• SACHS G, SHIN JM, BRIVING C, WALLMARK B, HERSEY S: The pharmacology of the gastric acid pump: the H+,K+ ATPase. Ann. Rev Pharmacol Toxicol (1995) 35:277–305.
   PubMed Web of Science ®Google Scholar
• SACHS G, SHIN JM, PRATHA V, HOGAN D: Synthesis or rupture: duration of acid inhibition by proton pump inhibitors. Drugs Today (Barc) (2003) 39(Suppl. A):11–14.
   Google Scholar
• GEDDA K, SCOTT D, BESANCON M, LORENTZON P, SACHS G: Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology (1995) 109(4):1134–1141.
   PubMed Web of Science ®Google Scholar
• ISHIZAKI T, HORAI Y: Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 3):27–36.
   Google Scholar
• •This paper details the metabolic pathways of the PPIs and draws up the interesting pharmacodynarnic profile for rabeprazole.
   Google Scholar
• SOHN DR, KOBAYASHI K, CHIBA K, LEE KH, SHIN SG, ISHIZAKI T: Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. J. Pharmacol Exp. The]: (1992) 262(3):1195–1202.
   PubMedGoogle Scholar
• YASUDA S, HORAI Y, TOMONO Y et al.: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin. Pharmacol Ther. (1995) 58(2):143–154.
   PubMedGoogle Scholar
• ADACHI K, KATSUBE T, KAWAMURA A et al.: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol Ther. (2000) 14(10):1259–1266.
   PubMed Web of Science ®Google Scholar
• •This paper indicates clinical relevance for the different metabolic pathways of lansoprazole in favour of rabeprazole.
   Google Scholar
• SAITOH T, FUKUSHIMA Y, OTSUKA H et al.: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol The]: (2002) 16(10):1811–1817.
   PubMedGoogle Scholar
• SHIRAI N, FURUTA T, MORIYAMA Y et al.: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol Ther. (2001) 15(12):1929–1937.
   PubMed Web of Science ®Google Scholar
• •This paper indicates clinical relevance for the different metabolic pathways of lansoprazole and omeprazole in favour of rabeprazole.
   Google Scholar
• SUKEGAWA M HK, TAKEDA H, SUGIYAMA T, KATO M, ASAKA M: Effect of lansoprazole and rabeprazole on intragastric acidity in relation to CYP2C19 genotype status. Gut (1999) 45 (Suppl. V):A105.
   Google Scholar
• KIM YPS, KIM J, LEE S et al: Effect of CYP2C19 polymorphism on intragastric pH during omeprazole and rabeprazole administration. Gastroenterol Hepatol (2002) 17(Suppl.):A792.
   Google Scholar
• KAWAMURA M, OHARA S, KOIKE T S et al.: The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol The]: (2003) 17(7):965–973.
   Google Scholar
• MORII M, HAMATANI K, TAKEGUCHI N: The proton pump inhibitor, E3810, binds to the N-terminal half of the alpha-subunit of gastric H+,K(+)-ATPase. Biochem. Pharmacol (1995) 49(12):1729–1734.
   PubMedGoogle Scholar
• PRAKASH A, FAULDS D: Rabeprazole. Drugs (1998) 55(2):261–267; Discussion:268.
   Google Scholar
• MORII M, TAKEGUCHI N: Different biochemical modes of action of two irreversible H+,K(+)-ATPase inhibitors, omeprazole and E3810. J. Biol. Chem. (1993) 268(29):21553–21559.
   PubMedGoogle Scholar
• MORII M, TAKATA H, FUJISAKI H, TAKEGUCHI N: The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+,K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. Biochem. Pharmacol (1990) 39(4):661–667.
   PubMedGoogle Scholar
• YASUDA S, OHNISHI A, OGAWA T et al.: Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int. .1. Clin. Pharmacol Ther. (1994) 32(9):4664–4673.
   Google Scholar
• SWAN SK, HOYUMPA AM, MERRITT GJ: Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 3):11–17.
   Google Scholar
• HUMPHRIES TJ, NARDI RV, LAZAR JD: Drug-drug interaction of rabeprazole sodium: a clean/expected slate? Gut (1996) 39\(Suppl. 3)47 (Abstract).
   Google Scholar
• WALSH J, POUNDER R, DAMMANN H, HUMPHRIES T: Rabeprazole 20 mg is optimal therapy for acute acid related diseases: pharmacodynamic mperspective. World Congress of Gastroenterology Vienna, Austria, 6–11 September (1998) (Abstract 340).
   Google Scholar
• WILLIAMS MP, BLANSHARD C, MILLSON C, SERCOMBE J, POUNDER RE: A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment. Pharmacol Ther. (2000) 14(6):691–699.
   PubMedGoogle Scholar
• PANTOFLICKOVA D, DORTA G, RAVIC M, JORNOD P, BLUM AL: Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol The]: (2003) 17(12):1507–1514.
   PubMedGoogle Scholar
• WILLIAMS MP, SERCOMBE J, HAMILTON MI, POUNDER RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol Ther. (1998) 12(11):1079–1089.
   PubMedGoogle Scholar
• WARRINGTON S, BAISLEY K, BOYCE M, TEJURA B, MOROCUTTI A, MILLER N: Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment. Pharmacol Ther. (2002) 16(7):1301–1307.
   PubMed Web of Science ®Google Scholar
• •This paper shows superior acid suppression for rabeprazole over esomeprazole at equivalent doses.
   Google Scholar
• WILDER-SMITH C RK, CLAAR-NILSSON C, RYDHOLM: Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut (2000) 47(Suppl. III):A63.
   Google Scholar
• BAISLEY K J WS, TEJURA B, MOROCUTTI A, MILLER N: Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gastroenterol Hepatology (2002) 17(Suppl.):A845.
   Google Scholar
• MINER P, ROBINSON M, GARDNER J et al.: Rabeprazole improves esophageal pH profiles more rapidly than omeprazole in gastroesophageal reflux disease. Am. Gastroenterol (2002) 97(Suppl):S25 (Abstract).
   Google Scholar
• ROBINSON M, MATON PN, RODRIGUEZ S, GREENWOOD B, HUMPHRIES TJ: Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol The]: (1997) 11(5)973–980.
   Google Scholar
• GALMICHE JP, ZERBIB F, DUCROTTE P et al.: Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole. Aliment. Pharmacol Ther. (2001) 15(9):1343–1350.
   PubMedGoogle Scholar
• GARDNER JD, PERDOMO C, SLOAN S et al.: Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol The]: (2002) 16(3):455–464.
   PubMedGoogle Scholar
• HOLTMANN G, BYTZER P, METZ M, LOEFFLER V, BLUM AL: A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment. Pharmacol The]: (2002) 16(3):479–485.
   PubMedGoogle Scholar
• ••A pivotal paper demonstrating the relevantclinical benefit from the rapid onset of action of rabeprazole.
   Google Scholar
• BYTZER P, BLUM A, DIRK DE HERDT: Fast and complete control of heartburn in on-demand rabeprazole maintenance therapy in patients with nonerosive reflux disease. Gastroenterology (2003) 124\(Suppl. 1):S–1596.
   Google Scholar
• BYTZER P, BLUM A, DIRK DE HERDT: On-demand rabeprazole therapy provides heartburn control in long-term management of nonerosive reflux disease (NERD). Gastroenterology (2003) 124\(Suppl. 1):S–1591.
   Google Scholar
• BOUR B, CHOUSTERMAN M, LABAYLE D et al: On-demand maintenance therapy with rabeprazole (rab) 10 mg: an effective alternative to continuous therapy for patients with frequent gastroesophageal reflux symptomatic relapse. Gastroenterology (2003) 124\(Suppl. 1):S1601.
   Google Scholar
• PAPAZIAN A, VARANNES SB, CORALLO J et al.: Two weeks of rabeprazole treatment is as effective as 4 weeks for relieving symptoms of gastroesophageal reflux disease. Gastroenterology (2003) 124\(Suppl. 1):S–1592.
   Google Scholar
• ROBINSON M, FITZGERALD S, HEGEDUS R, MURTHY A, JOKUBAMS L: Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment. Pharmacol Ther. (2002) 16(3):445–454.
   PubMedGoogle Scholar
• MINER P Jr, ORR W, FILIPPONE J, JOKUBAITIS L, SLOAN S: Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. Gastroenterol (2002) 97(6):1332–1339.
   PubMedGoogle Scholar
• •This paper demonstrates the efficacy of rabeprazole in the treatment of non-erosive GERD.
   Google Scholar
• DAMIANO A, SIDDIQUE R, XU X, JOHANSON J, SLOAN S: Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole. Dig. Dis. Sci. (2003) 48(4):657–662.
   PubMedGoogle Scholar
• CLOUD ML, ENAS N, HUMPHRIES TJ,BASSION S: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig. Dis. Sci. (1998) 43(5):993–1000.
   PubMedGoogle Scholar
• DEKKERS CP, BEKERJA, THJODLEIFSSON B, GABRYELEWICZ A, BELL NE, HUMPHRIES TJ: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment. Pharmacol Ther. (1999) 13(1):49–57.
   PubMedGoogle Scholar
• •This paper demonstrates the efficacy of rabeprazole and omeprazole in GERD healing.
   Google Scholar
• DELCHIER JC, COHEN G, HUMPHRIES TJ: Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease. Scand. Gastroenterol (2000) 35(12):1245–1250.
   PubMedGoogle Scholar
• FARLEY A, WRUBLE LD, HUMPHRIES TJ: Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. Am. Gastroenterol (2000) 95(8):1894–1899.
   PubMed Web of Science ®Google Scholar
• HALL J, DODD S, DURKIN M, SLOAN S: Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag. Care (2002) 11(7 Suppl.):14–18.
   Google Scholar
• ••A pivotal paper demonstrating superiorcost-effectiveness of rabeprazole in the treatment of erosive GERD over omeprazole and lanzoprazole.
   Google Scholar
• OFMAN JJ, YAMASHITA BD, SIDDIQUE RM, LARSON LR, WILLIAN MK: Cost effectiveness of rabeprazole versus generic ranitidine for symptom resolution in patients with erosive esophagitis. Am. Manag. Care (2000) 6(8):905–916.
   PubMedGoogle Scholar
• CAOS A, MOSKOVITZ M, DAYAL Y, PERDOMO C, NIECESTRO R, BARTH J: Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rabeprazole Study Group. Am. J. Gastroenterol (2000) 95(11):3081–3088.
   PubMedGoogle Scholar
• BIRBARA C, BREITERJ, PERDOMO C, HAHNE W: Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. Eur. I Gastroenterol Hepatol (2000) 12(8):889–897.
   PubMedGoogle Scholar
• THJODLEIFSSON B, RINDI G, FIOCCA R et al.: A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment. Pharmacol Ther. (2003) 17(3):343–351.
   PubMedGoogle Scholar
• ••A pivotal study demonstrating the safetyand efficacy of rabeprazole 10 and 20 mg and omeprazole 20 mg in maintaining healing in erosive GERD. The study included 243 patients and 123 remained in the study for 5 years.
   Google Scholar
• CAOS A BJ, BIRBARA C, MOSKOVITZ M, BARTH J: Rabeprazole improves and maintains overall well being in gastroesophageal reflux disease over 5 years. Gastroenterology (2003) 124\(Suppl. 1):S–1602.
   Google Scholar
• KRISTENSEN ES, ALSTRUP N, HENDEL L et al.: Rabeprazole 10 mg effectively controls symptoms of gastroesophageal reflux disease over 1 year. Gastroenterology (2003) 124\(Suppl. 1).
   Google Scholar
• DEAN BB, SIDDIQUE PM, YAMASHITA BD, BHATTACHARJYA AS, OFMAN JJ: Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis. Am. J. Health Syst. Pharm. (2001) 58(14):1338–1346.
   PubMedGoogle Scholar
• JOHNSON D, RIFF R, PERDOMO C, JASKIR J, NIECESTRO R, HAHNE W: Rabeprazole: Safety profile of a new proton pump inhibitor. Gastroenterology (1999) 116:A 201 (Abstract).
   Google Scholar
• THJODLEIFSSON B, COCKBURN I: Review article: rabeprazole's tolerability profile in clinical trials. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 5):17–23.
   Google Scholar
• ROBINSON M: Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment. Pharmacol Ther. (1999) 13\(Suppl. 5):5–10.
   Google Scholar
• RINDI G, FIOCCA R, MOROCUTTI A, JACOBS A, MILLER N, THJODLEIFSSON B: Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Scand. Gastroentrol (2003) (Submitted).
   Google Scholar
• THJODLEIFSSON B, MILLER NM, BARDHAN KD: A 5-year, double blind,randomized comparison of rabeprazole and omeprazole in GORD maintenance treatment: Gastric biopsy results. Gut (2002) (Suppl. 11):A 239.
   Google Scholar
• THJODLEIFSSON B, MILLER NM, SALTER JE, BARDHAN KD: A 5-year, double blind,randomized comparison of rabeprazole and omeprazole in GORD maintenance treatment: Serum gastrin results. Gut (2002) 50\(Suppl. 11):A458.
   Google Scholar
• HUMPHRIES TJ, NARDI RV, SPERA AC: Co-administration of rabeprazole sodium (E3810) does not effect the pharmacolkinetics of anhydrous theophylline or warfarin. Gastroenterology (1996) 110:A138 (Abstract).
   Google Scholar
• LUNDELL L, ABRAHAMSSON H, RUTH M, RYDBERG L, LONROTH H, OLBE L: Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br. Surg. (1996) 83(6):830–835.
   PubMedGoogle Scholar
• PERDIKIS G, HINDER RA, LUND RJ,RAISER F, KATADA N: Laparoscopic Nissen fundoplication: where do we stand? Surg. Laparosc. Enclose. (1997) 7(1):17–21.
   PubMedGoogle Scholar